Search results for "Psoriasis."

showing 10 items of 191 documents

Secukinumab efficacy in the treatment of nail psoriasis: a case series

2018

Nail involvement is frequent in patients with psoriasis, especially those with psoriatic arthritis (PsA), and can significantly impair quality of life (QoL). It is typically difficult to treat compared with skin lesions, although several conventional treatment options are available. The aim of this article is to describe our experience in the treatment of nail psoriasis with secukinumab in a case series. Fifteen patients (11 males and 4 females), with moderate-severe plaque psoriasis and nail psoriasis, eligible for systemic therapy, and received secukinumab. The Psoriasis Area and Severity Index (PASI) and body surface area (BSA) assessed cutaneous severity. Nail Psoriasis Severity Index (…

0301 basic medicineAdultMalemedicine.medical_specialtyDermatologyNail psoriasisAntibodies Monoclonal HumanizedSeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisNail Diseases0302 clinical medicineQuality of lifePsoriasisSeverity of illnessMedicineHumansPsoriasisIn patientPsoriasibusiness.industrysecukinumabfungifood and beveragesAntibodies MonoclonalMiddle Agedmedicine.diseaseNail DiseaseDermatologyhumanities030104 developmental biologyNAPSITreatment OutcomeNail diseasenail psoriasiQuality of LifeSecukinumabFemalebusinessHuman2708
researchProduct

Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities

2019

The oleogum resins of Boswellia species known as frankincense have been used for ages in traditional medicine in India, China and the Arabian world independent of its use for cultural and religious rituals in Europe. During the past two decades, scientific investigations provided mounting evidence for the therapeutic potential of frankincense. We conducted a systematic review on the anti-inflammatory and anti-cancer activities of Boswellia species and their chemical ingredients (e.g. 3-O-acetyl-11-keto-β boswellic acid, α- and β-boswellic acids, 11-keto-β-boswellic acid and other boswellic acids, lupeolic acids, incensole, cembrenes, triterpenediol, tirucallic acids, and olibanumols). Frank…

0301 basic medicineCancer Researchmedicine.drug_classAnti-Inflammatory AgentsPharmacologyAnti-inflammatory03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemPsoriasismedicineHumansImmunologic FactorsBoswelliaAdverse effectBoswelliabiologybusiness.industryCancerGliomaFrankincenseFrankincensemedicine.diseasebiology.organism_classification030104 developmental biologychemistry030220 oncology & carcinogenesisBoswellic acidbusinessResins PlantSeminars in Cancer Biology
researchProduct

Hydroxyurea‑induced superinfected ulcerations: Two case reports and review of the literature

2020

The chronic use of hydroxyurea (HU) in some oncologic and non-oncologic diseases (psoriasis, sickle cell anemia) can be accompanied by side effects, both systemic and mucocutaneous. The most severe adverse events known in HU therapy are leg ulcers and cutaneous carcinomas. At skin level may also appear: xerosis, persistent pruritus, skin color changes (erythema, hyperpigmentation), cutaneous atrophy. Likewise, oral ulcerations and stomatitis may occur at mucosal level. Hair damage can be expressed through alopecia and nail damage through melanonychia and oncycholysis. First case, a 63-year-old woman with severe psoriasis vulgaris and chronic granulocytic leukemia, with 5 years of HU therapy…

0301 basic medicineCancer Researchmedicine.medical_specialtyErythemaMucocutaneous zoneleg ulcersmedicine.disease_causehydroxyurea03 medical and health sciences0302 clinical medicineImmunology and Microbiology (miscellaneous)PsoriasismedicineStomatitiscutaneousbusiness.industrysuperinfectedArticlesGeneral Medicinemedicine.diseaseHyperpigmentationDermatologyside effects030104 developmental biologyMelanonychia030220 oncology & carcinogenesisCellulitisSuperinfectionmedicine.symptombusinessExperimental and Therapeutic Medicine
researchProduct

Importance of food in the control of inflammation in atopic dermatitis

2020

Patients that suffer from inflammatory diseases need to pay special attention to nutrition. For this reason, it is very important to change the approach of both health professionals and food industry specialists. There must be a close collaboration, starting from research, the development phase of foods for special nutrition states. Our primary objective was to identify foods or potential dietary ingredients, which efficacy in the treatment of atopic dermatitis had been scientifically demonstrated in vitro, in vivo and clinically. Furthemore, our perspective is presented regarding the research and development of foods for special nutritional states in atopic dermatitis. The PubMed database …

0301 basic medicineCancer Researchmedicine.medical_specialtyHealth professionalsbusiness.industryArticlesGeneral MedicineAtopic dermatitisMultidisciplinary teammedicine.diseasebody regions03 medical and health sciences030104 developmental biology0302 clinical medicineImmunology and Microbiology (miscellaneous)030220 oncology & carcinogenesisPsoriasismedicineIntensive care medicinebusinessChronic dermatitisExperimental and Therapeutic Medicine
researchProduct

E-Cadherin is Dispensable to Maintain Langerhans Cells in the Epidermis.

2019

The cell adhesion molecule E-cadherin is a major component of adherens junctions and marks Langerhans cells (LC), the only dendritic cell (DC) population of the epidermis. LC form a dense network and attach themselves to the surrounding keratinocytes via homophilic E-cadherin binding. LC activation, mobilization, and migration require a reduction in LC E-cadherin expression. To determine whether E-cadherin plays a role in regulating LC homeostasis and function, we generated CD11c-specific E-cadherin knockout mice (CD11c-Ecaddel). In the absence of E-cadherin−mediated cell adhesion, LC numbers remained stable and similar as in control mice, even in aged animals. Intriguingly, E-cadherin−defi…

0301 basic medicineCellular differentiationPopulationDermatologyDermatitis ContactBiochemistryAdherens junction03 medical and health sciencesMice0302 clinical medicineCell MovementAnimalsHomeostasisHumansPsoriasisCell adhesioneducationMolecular BiologyCell ShapeCells CulturedMice Knockouteducation.field_of_studyImiquimodEpidermis (botany)CadherinCell adhesion moleculeChemistryCell DifferentiationCell BiologyDendritic cellCadherinsCell biologyCD11c AntigenDisease Models Animal030104 developmental biology030220 oncology & carcinogenesisLangerhans CellsEpidermisThe Journal of investigative dermatology
researchProduct

Gradual development of psoriatic skin lesions by constitutive low-level expression of IL-17A

2016

Psoriasis is a common chronic inflammatory skin disease restricted to humans. The understanding of its pathogenesis has long been hampered by the lack of suitable chronic mouse models. The cytokine IL-17A has emerged as a key player in epithelial immune responses and the defense against extracellular pathogens. Moreover, enhanced expression of IL-17A can turn pathologic and is closely associated with psoriasis. In this study, we generated a novel transgenic mouse model that recapitulates many characteristics of psoriasis. DC-1L-17A(ind) mice with constitutive low-level expression of IL-17A by CD11c(+) cells gradually develop skin lesions during adult life. The lesions preferentially occur a…

0301 basic medicineGenetically modified mousemedicine.medical_treatmentImmunologyCD11cInflammationAnimals Genetically ModifiedPathogenesisMice03 medical and health sciences0302 clinical medicineImmune systemSDG 3 - Good Health and Well-beingPsoriasismedicineAnimalsHumansPsoriasisCells CulturedSkinbusiness.industryInterleukin-17Dendritic Cellsmedicine.diseaseCD11c AntigenDisease Models Animal030104 developmental biologyCytokineImmunologyCytokinesInterleukin 17medicine.symptombusiness030215 immunologyCellular Immunology
researchProduct

Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis

2019

Besides skin inflammation, patients with severe psoriasis suffer from an increased risk of cardiovascular mortality. IL-17A plays a central role in the development of psoriasis and might connect skin and vascular disease. The aim of this study was to clarify whether anti-IL-17A therapy could also ameliorate the vascular dysfunction associated with severe psoriasis. We analyzed three murine models with varying severities of psoriasis-like skin disease concerning their vascular function and inflammation: (i) K14-IL-17A(ind/+) mice with keratinocyte-specific IL-17A overexpression and an early-onset severe psoriasis-like phenotype; (ii) homozygous CD11c-IL-17A(ind/ind) and heterozygous CD11c-IL…

0301 basic medicineInflammationDermatologyDiseasemedicine.disease_causeBiochemistryProinflammatory cytokine03 medical and health sciencesMice0302 clinical medicinePsoriasis Area and Severity IndexPsoriasismedicineAnimalsHumansPsoriasisVascular DiseasesAntibodies BlockingMolecular BiologyAortaSkinInflammationImiquimodintegumentary systembusiness.industryVascular diseaseInterleukin-17Cell Biologymedicine.diseaseAngiotensin II3. Good healthMice Inbred C57BLDisease Models AnimalOxidative Stress030104 developmental biologyNeutrophil Infiltration030220 oncology & carcinogenesisImmunologyDisease Progression[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunotherapymedicine.symptombusinessReactive Oxygen SpeciesOxidative stress
researchProduct

Keratinocyte-derived IκBζ drives psoriasis and associated systemic inflammation.

2019

The transcriptional activator IκBζ is a key regulator of psoriasis, but which cells mediate its pathogenic effect remains unknown. Here we found that IκBζ expression in keratinocytes triggers not only skin lesions but also systemic inflammation in mouse psoriasis models. Specific depletion of IκBζ in keratinocytes was sufficient to suppress the induction of imiquimod- or IL-36–mediated psoriasis. Moreover, IκBζ ablation in keratinocytes prevented the onset of psoriatic lesions and systemic inflammation in keratinocyte-specific IL-17A–transgenic mice. Mechanistically, this psoriasis protection was mediated by IκBζ deficiency in keratinocytes abrogating the induction of specific proinflammato…

0301 basic medicineKeratinocytesMaleAutoimmune diseasesInflammationMice TransgenicAutoimmunityDermatologySystemic inflammationmedicine.disease_causeAutoimmunityProinflammatory cytokine03 medical and health sciencesMice0302 clinical medicinePsoriasismedicineAnimalsPsoriasisCells CulturedAdaptor Proteins Signal TransducingSkinInflammationInnate immunityInnate immune systembusiness.industryInterleukin-17General Medicinemedicine.diseaseCXCL2030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchFemalemedicine.symptomKeratinocytebusinessResearch ArticleJCI insight
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct

Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts

2016

Item does not contain fulltext Inflammation has important roles in tissue regeneration, autoimmunity, and cancer. Different inflammatory stimuli can lead to bone loss by mechanisms that are not well understood. We show that skin inflammation induces bone loss in mice and humans. In psoriasis, one of the prototypic IL-17A-mediated inflammatory human skin diseases, low bone formation and bone loss correlated with increased serum IL-17A levels. Similarly, in two mouse models with chronic IL-17A-mediated skin inflammation,K14-IL17A(ind)andJunB(Deltaep), strong inhibition of bone formation was observed, different from classical inflammatory bone loss where osteoclast activation leads to bone deg…

0301 basic medicineMaleInflammationModels BiologicalOsteocytesBone resorptionEpithelium03 medical and health sciences0302 clinical medicineOsteoclastOsteogenesismedicineAnimalsHumansPsoriasisCell LineageBone ResorptionWnt Signaling PathwaySkin030203 arthritis & rheumatologyInflammationOsteoblastsChemistryInnate lymphoid cellInterleukin-17Wnt signaling pathwayOsteoblastGeneral MedicineMiddle AgedMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureGene Expression RegulationOsteocyteImmunologyChronic DiseaseCancer researchFemaleInterleukin 17medicine.symptomInflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]Science Translational Medicine
researchProduct